VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
                   
redorbit.com     May 22, 2008            

SAN DIEGO, May 22 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the appointment of Dr. [read full story]                

Add a comment to the article
Type the code shown

View all news articles about:

- Related Topics

View other selected articles:

Plant Steroids Offer New Paradigm For How Hormones Work

medicalnewstoday.com     15 mins ago          

Steroids bulk up plants just as they do human athletes, but the playbook of molecular signals that tell the genes to boost growth and development in plant cells is far more complicated than in human and animal cells. A new...                

comments

                   

GPs Must Remain At The Centre Of Patient Care, Royal Australian College Of General Practitioners

medicalnewstoday.com     16 mins ago   1 related          

In a proposal to the Federal Government, the Pharmacy Guild of Australia is recommending that pharmacists should be allowed to write repeat scripts for chronic conditions for up to 12 months as well as writing repeat scripts...                

comments

Patient Safety Paramount In Medication Prescriptions, Australian Medical Association

medicalnewstoday.com     17 mins ago          

Doctors must maintain sole responsibility for prescribing medication to patients, AMA (Australian Medical Association) President, Dr Rosanna Capolingua said today. "No medication is without risk," Dr Capolingua said. "The right...                

comments

                   

The State of Statins and Stents (at Seeking Alpha)

yahoo.com     20 mins ago   1 related          

by: Mike Huckman posted on: July 27, 2008 | about stocks: Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck . Leerink has a...                

comments